AstraZeneca China President Detained: Medical Insurance Fraud Investigation Triggers Stock Market Turmoil

AstraZeneca announced on Wednesday that its China chief, Leon Wang, had been detained by Chinese authorities. Although the specific reason for the detention is unclear, the company said it does not believe the incident is related to a major health insurance fraud case involving its company.

A week ago, Astrazeneca said Wang was under investigation and pledged to cooperate actively with the relevant authorities. Wang grew up in China and has worked at Astrazeneca for more than a decade. Astrazeneca Chief Financial Officer Aradhana Sarin briefed investment analysts on Wednesday in an effort to calm fears that the fraud probe could widen. Earlier, the report by financial media CBN sent Astrazeneca shares tumbling more than 8 percent on Tuesday.

The company also informed shareholders of the incident on Wednesday. Astrazeneca has invested heavily in the Chinese market and sees its business as a core part of achieving its annual revenue target by the end of the decade. A report by Yicai on Tuesday said several of the pharmaceutical company's top executives in China may be linked to the largest health insurance fraud in the country's history. However, Astrazeneca stressed in a statement on Wednesday that the case so far does not implicate any of the company's current executives.

Astrazeneca shares, which had their worst day since March 2020 on Tuesday, closed down 1.9 percent on Wednesday. Tuesday's drop wiped about $14 billion off the company's market value. This follows reports that Chinese authorities have summoned Astrazeneca executives in an investigation into alleged health insurance fraud among employees and demanded that the company strengthen marketing compliance.

Astrazeneca said the current investigation, which began three years ago and initially involved only a handful of employees, has since expanded to around 100 former employees who have been jailed. The investigation focuses on Tagrisso, the company's best-selling lung cancer drug, which has performed strongly in China, where lung cancer rates are higher than in other regions.

Separately, Astrazeneca also noted that in addition to the insurance investigation and Wang's situation, China is also conducting a third investigation into two current and two former executives related to the import of cancer drugs Imjudo and Enhertu from Hong Kong to the mainland. A company statement stressed that the survey was conducted on individuals, not the company as a whole.

An Astrazeneca shareholder who attended an investor relations briefing told Reuters that while the tone of the company's communications appeared reassuring, there were still limits to transparency. He added that the sensitivity of the situation complicates concerns about whether the problem could escalate further. Astrazeneca employs about 12,000 people in India, while China accounts for 13 per cent of its sales. Analysts at Barclays said in a note that the stock sell-off "appears overdone" and that current share price levels represent a "very attractive entry point" until 2025, when a number of highly anticipated clinical trial data are expected to be released.